Trade Names:Albenza- Tablets 200 mg
Inhibits effect on tubulin polymerization, resulting in loss of cytoplasmic microtubules.
Albendazole is poorly absorbed from the GI tract; however, it is rapidly converted to its primary active metabolite, albendazole sulfoxide, prior to reaching systemic circulation. Fatty meals enhance bioavailability, as indicated by up to a 5-fold increase in plasma concentration in albendazole sulfoxide. Albendazole sulfoxide plasma concentrations are dose dependent. C max is achieved in 2 to 5 h and ranges from 0.46 to 1.58 mcg/mL, with a fatty meal.
Albendazole sulfoxide is 70% protein bound and widely distributed throughout the body.
After metabolism in the liver to albendazole sulfoxide, it is further metabolized to albendazole sulfone and other oxidative metabolites.
Albendazole sulfoxide elimination t ½ is 8 to 12 h. Biliary elimination of albendazole sulfoxide results in biliary concentrations similar to plasma concentration. Urinary excretion is a minor elimination pathway (less than 1%).
Systemic availability of albendazole sulfoxide is increased in patients with extrahepatic obstruction.
Treatment of parenchymal neurocysticercosis caused by larval forms of pork tapeworm, Taenia solium ; treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by larval forms of dog tapeworm, Echinococcus granulosus .
Hypersensitivity to benzimidazole compounds or any component of the product.
PO For patients weighing 132 lb (60 kg) or more, administer 400 mg twice daily with meals for a 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles. For patients weighing less than 132 lb (60 kg), administer 15 mg/kg/day in divided doses twice daily with meals (max, 800 mg/day) for a 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles. In the presurgical or postsurgical setting, optimal killing of cyst contents is achieved with 3 courses of therapy.Neurocysticercosis
PO For patients weighing 132 lb (60 kg) or more, administer 400 mg twice daily with meals for 8 to 30 days. For patients weighing less than 132 lb (60 kg), administer 15 mg/kg/day in divided doses twice daily with meals (max, 800 mg/day) for 8 to 30 days.
Store between 68° and 77°F.
In hydatid cyst patients, albendazole sulfoxide concentrations in bile and cystic fluid may be increased about 2-fold; however, plasma levels are unchanged 4 h after dosing.Dexamethasone
Albendazole C trough at steady state was about 56% higher when coadministered with dexamethasone 8 mg.Grapefruit juice
Plasma concentrations may be elevated and the t ½ may be shortened.Praziquantel
Albendazole sulfoxide C max may be elevated about 50%, increasing the risk of adverse reactions.Theophylline
Although theophylline pharmacokinetics are unchanged by albendazole, monitor plasma concentrations during and after albendazole treatment.
None well documented.
Headache (11%); raised intracranial pressure (2%); dizziness/vertigo, meningeal signs (1%).
Reversible alopecia (2%); erythema multiforme, hypersensitivity including rash and urticaria (less than 1%); Stevens-Johnson syndrome (postmarketing).
Abdominal pain, nausea/vomiting (6%).
Acute renal failure (postmarketing).
Abnormal LFTs (16%); hepatitis (postmarketing).
Leukopenia (less than 1%); agranulocytosis, granulocytopenia, pancytopenia, thrombocytopenia (rare); aplastic anemia (postmarketing).
Monitor blood cell counts and liver function (transaminases) at the beginning of each 28-day cycle of therapy and every 2 wk while on therapy. Discontinue therapy if liver enzymes are significantly increased. Treatment can be resumed when hepatic enzymes have returned to pretreatment levels, but perform lab tests frequently during repeat therapy.
Category C .
Experience in children younger than 6 yr of age is limited.
Rare deaths due to granulocytopenia or pancytopenia have been reported.
Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as needed. Consider using oral or IV corticosteroids to prevent cerebral hypertensive episodes during the first week of therapy.
No untoward effects have been reported with doses of at least 16 g over 12 h.
Copyright © 2009 Wolters Kluwer Health.